The concept of precision drug-dosing has gained ground in recent years, given its ability to boost efficacy and curb side effects. Yet imprecise dosing regimens continue to be common for many drugs, leading to significant rates of adverse drug reactions (ADRs).
“ADRs are one of the top ten causes of death in the developed world,” said Sirj Goswami, CEO and co-founder of InsightRX. “More than two million serious ADRs occur each year, representing a cost burden of $136 billion annually. More than half of these events are preventable and are dose-related,” Goswami said.
In the following interview, Goswami shares his perspective on how precision dosing can optimize dosing in clinical trials and improve real-world drug performance. He also touches on the promise of machine learning to drive further dosing-related advances.
Read More on the Drug Discovery and Development post.
